- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Wedbush initiates Hemab Therapeutics stock with outperform rating | 1 | Investing.com | ||
| Di | Jefferies stuft Hemab Therapeutics mit "Buy" ein - Hohes Potenzial bei seltenen Blutgerinnungsstörungen | 1 | Investing.com Deutsch | ||
| Di | Jefferies initiates Hemab Therapeutics stock with buy rating on rare bleeding disorder potential | 1 | Investing.com | ||
| Di | Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential | 2 | Investing.com | ||
| Di | Goldman Sachs stuft Hemab Therapeutics mit "Buy" ein - Potenzial durch Medikament für seltene Krankheiten | 1 | Investing.com Deutsch | ||
| 21.05. | Hemab Therapeutics Holdings, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 21.05. | Hemab Therapeutics Holdings, Inc. GAAP EPS of -$23.98 | 1 | Seeking Alpha | ||
| 21.05. | Hemab Therapeutics, Inc.: Hemab Therapeutics Reports First Quarter 2026 Financial Results | 180 | GlobeNewswire (Europe) | Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE... ► Artikel lesen | |
| 21.05. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.05. | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 75 | GlobeNewswire (Europe) | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine... ► Artikel lesen | |
| 04.05. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.05. | Hemab Therapeutics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 01.05. | Hemab, Seaport Therapeutics surge as clinical-stage biotechs make trading debuts | 1 | Seeking Alpha | ||
| 01.05. | Hemab Therapeutics prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| 01.05. | Hemab Therapeutics prices IPO at $18 per share | 1 | Investing.com | ||
| 01.05. | Hemab Therapeutics, Inc.: Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering | 172 | GlobeNewswire (Europe) | CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine... ► Artikel lesen | |
| 30.04. | Bleeding disorder firm Hemab upsizes proposed IPO to 15M shares | 1 | Seeking Alpha | ||
| 30.04. | Coagulation disorder biotech Hemab Therapeutics Holdings ups shares offered by 27% ahead of $255 million IPO | 1 | Renaissance Capital | ||
| 28.04. | Seaport Therapeutics and Hemab target $180m IPOs as biotech listings accumulate | 1 | Pharmaceutical Technology |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,110 | -7,47 % | Bernstein reiterates Summit Therapeutics stock Underperform on trial concerns | ||
| ERASCA | 14,650 | +20,08 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| QIAGEN | 30,815 | -2,21 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 39,080 | +14,40 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,170 | +0,60 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,605 | +4,80 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| CG ONCOLOGY | 59,21 | -2,50 % | CG Oncology, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 23,280 | +16,40 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| IMMUNEERING | 4,440 | -23,05 % | Immuneering Corporation: Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO | - 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related... ► Artikel lesen | |
| JADE BIOSCIENCES | 19,480 | -7,41 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| BEAM THERAPEUTICS | 31,400 | -4,27 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ABSCI | 6,450 | +6,09 % | BTIG initiates Absci stock with buy rating on AI drug platform | ||
| IMMUNOVANT | 32,580 | -2,16 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 30,990 | -1,74 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection ... | - Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease - - In participants... ► Artikel lesen | |
| EVOTEC | 5,305 | +3,82 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen |
Das Unternehmen HEMAB THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,43 % bei einem Aktienkurs von 26,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMAB THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.